Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.07
XTNT's Cash-to-Debt is ranked lower than
99% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. XTNT: 0.07 )
Ranked among companies with meaningful Cash-to-Debt only.
XTNT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.13 Max: No Debt
Current: 0.07
0.01
No Debt
Equity-to-Asset 0.13
XTNT's Equity-to-Asset is ranked lower than
95% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. XTNT: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
XTNT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.56  Med: 0.07 Max: 0.85
Current: 0.13
-0.56
0.85
Debt-to-Equity 6.06
XTNT's Debt-to-Equity is ranked lower than
99.99% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. XTNT: 6.06 )
Ranked among companies with meaningful Debt-to-Equity only.
XTNT' s Debt-to-Equity Range Over the Past 10 Years
Min: -245.75  Med: 0.51 Max: 33.47
Current: 6.06
-245.75
33.47
Debt-to-EBITDA -3.31
XTNT's Debt-to-EBITDA is ranked lower than
99.99% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. XTNT: -3.31 )
Ranked among companies with meaningful Debt-to-EBITDA only.
XTNT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.62  Med: -2.95 Max: 2143.39
Current: -3.31
-15.62
2143.39
Piotroski F-Score: 2
Altman Z-Score: -1.82
Beneish M-Score: -3.51
WACC vs ROIC
8.59%
-6.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -7.73
XTNT's Operating Margin % is ranked lower than
64% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. XTNT: -7.73 )
Ranked among companies with meaningful Operating Margin % only.
XTNT' s Operating Margin % Range Over the Past 10 Years
Min: -55.87  Med: -16.07 Max: -3.49
Current: -7.73
-55.87
-3.49
Net Margin % -57.08
XTNT's Net Margin % is ranked lower than
70% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. XTNT: -57.08 )
Ranked among companies with meaningful Net Margin % only.
XTNT' s Net Margin % Range Over the Past 10 Years
Min: -126.27  Med: -26.57 Max: -3.49
Current: -57.08
-126.27
-3.49
ROA % -38.66
XTNT's ROA % is ranked lower than
67% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. XTNT: -38.66 )
Ranked among companies with meaningful ROA % only.
XTNT' s ROA % Range Over the Past 10 Years
Min: -148.33  Med: -31.87 Max: -2.57
Current: -38.66
-148.33
-2.57
ROC (Joel Greenblatt) % -103.09
XTNT's ROC (Joel Greenblatt) % is ranked lower than
63% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. XTNT: -103.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XTNT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -314.89  Med: -54.96 Max: -20.26
Current: -103.09
-314.89
-20.26
3-Year Revenue Growth Rate -5.70
XTNT's 3-Year Revenue Growth Rate is ranked lower than
57% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. XTNT: -5.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XTNT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.7 Max: 40.7
Current: -5.7
0
40.7
3-Year EBITDA Growth Rate -39.30
XTNT's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. XTNT: -39.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XTNT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.7 Max: 32.9
Current: -39.3
0
32.9
3-Year EPS without NRI Growth Rate -21.50
XTNT's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. XTNT: -21.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XTNT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4 Max: 47.4
Current: -21.5
0
47.4
GuruFocus has detected 5 Warning Signs with Xtant Medical Holdings Inc XTNT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XTNT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

XTNT Guru Trades in Q4 2017

Jim Simons 291,892 sh (+145.72%)
» More
Q1 2018

XTNT Guru Trades in Q1 2018

Robert Bruce 296,172 sh (New)
Jim Simons 40,248 sh (-86.21%)
» More
Q2 2018

XTNT Guru Trades in Q2 2018

Jim Simons 43,648 sh (+8.45%)
Robert Bruce 182,972 sh (-38.22%)
» More
Q3 2018

XTNT Guru Trades in Q3 2018

Jim Simons 50,348 sh (+15.35%)
Robert Bruce 182,972 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AMEX:XTNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 5047
Compare:OTCPK:IVOB, XPAR:MKEA, OSTO:BACTI B, XKRX:004080, LSE:BQE, OTCPK:BBLG, TSX:TMD, XKRX:041920, XKRX:156100, XKRX:043100, XKRX:149980, XKRX:056090, OTCPK:BTCY, NAS:EYES, OSTO:IRRAS, OTCPK:ZYXI, TPE:4106, NAS:APEN, NAS:SRTS, TSE:5187 » details
Traded in other countries:XMS.Germany,
Headquarter Location:USA
Xtant Medical Holdings Inc develops, manufactures & markets biologics products to domestic and international markets. Its products are used in treatment of spinal disease, tissue grafts for orthopedic disorders and foot and ankle surgeries.

Xtant Medical Holdings Inc mainly develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The company operates through the single segment of Development, manufacture, and marketing of regenerative medical products and devices. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants, and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders and others.

Ratios

vs
industry
vs
history
PB Ratio 3.43
XTNT's PB Ratio is ranked lower than
99.99% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. XTNT: 3.43 )
Ranked among companies with meaningful PB Ratio only.
XTNT' s PB Ratio Range Over the Past 10 Years
Min: 3.08  Med: 8.57 Max: 253.36
Current: 3.43
3.08
253.36
PS Ratio 0.18
XTNT's PS Ratio is ranked higher than
98% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. XTNT: 0.18 )
Ranked among companies with meaningful PS Ratio only.
XTNT' s PS Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.68 Max: 20.09
Current: 0.18
0.05
20.09
Price-to-Free-Cash-Flow 14.57
XTNT's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. XTNT: 14.57 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
XTNT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.88  Med: 14.61 Max: 20.53
Current: 14.57
13.88
20.53
Price-to-Operating-Cash-Flow 8.67
XTNT's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. XTNT: 8.67 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
XTNT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.27  Med: 19.2 Max: 36.56
Current: 8.67
8.27
36.56
EV-to-EBIT -3.88
XTNT's EV-to-EBIT is ranked lower than
99.99% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. XTNT: -3.88 )
Ranked among companies with meaningful EV-to-EBIT only.
XTNT' s EV-to-EBIT Range Over the Past 10 Years
Min: -72.1  Med: -10.3 Max: -3.1
Current: -3.88
-72.1
-3.1
EV-to-EBITDA -4.99
XTNT's EV-to-EBITDA is ranked lower than
99.99% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. XTNT: -4.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
XTNT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -151.3  Med: -11.55 Max: 2258.4
Current: -4.99
-151.3
2258.4
EV-to-Revenue 1.57
XTNT's EV-to-Revenue is ranked higher than
63% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. XTNT: 1.57 )
Ranked among companies with meaningful EV-to-Revenue only.
XTNT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 1.7 Max: 22.5
Current: 1.57
0.9
22.5
Current Ratio 3.63
XTNT's Current Ratio is ranked lower than
95% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. XTNT: 3.63 )
Ranked among companies with meaningful Current Ratio only.
XTNT' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.94 Max: 6.87
Current: 3.63
0.47
6.87
Quick Ratio 1.50
XTNT's Quick Ratio is ranked lower than
98% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. XTNT: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
XTNT' s Quick Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.9 Max: 4.93
Current: 1.5
0.19
4.93
Days Inventory 309.50
XTNT's Days Inventory is ranked lower than
83% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. XTNT: 309.50 )
Ranked among companies with meaningful Days Inventory only.
XTNT' s Days Inventory Range Over the Past 10 Years
Min: 24.59  Med: 298.91 Max: 566.49
Current: 309.5
24.59
566.49
Days Sales Outstanding 49.16
XTNT's Days Sales Outstanding is ranked higher than
68% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. XTNT: 49.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
XTNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.73  Med: 77.64 Max: 94.62
Current: 49.16
45.73
94.62
Days Payable 80.75
XTNT's Days Payable is ranked higher than
69% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. XTNT: 80.75 )
Ranked among companies with meaningful Days Payable only.
XTNT' s Days Payable Range Over the Past 10 Years
Min: 48.23  Med: 123.26 Max: 245.21
Current: 80.75
48.23
245.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -35.60
XTNT's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. XTNT: -35.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XTNT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -169.2  Med: -35.6 Max: 0
Current: -35.6
-169.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.26
XTNT's Price-to-Median-PS-Value is ranked higher than
97% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. XTNT: 0.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XTNT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.99 Max: 28.29
Current: 0.26
0.11
28.29
Earnings Yield (Greenblatt) % -25.59
XTNT's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. XTNT: -25.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XTNT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -31.9  Med: -9.8 Max: -1.4
Current: -25.59
-31.9
-1.4

More Statistics

Revenue (TTM) (Mil) $73.27
EPS (TTM) $ -20.12
Beta-0.18
Volatility44.40%
52-Week Range $2.81 - 11.49
Shares Outstanding (Mil)13.17

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}